B
11.97
0.05 (0.42%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | Bicara Therapeutics Inc. | Bearish | - |
AIStockmoo Score
1.6
Analyst Consensus | 3.0 |
Insider Activity | NA |
Price Volatility | 0.5 |
Technical Moving Averages | 5.0 |
Technical Oscillators | -2.0 |
Average | 1.63 |
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. |
|
Sector | Healthcare |
Industry | Biotechnology |
% Held by Insiders | 6.26% |
% Held by Institutions | 69.97% |
52 Weeks Range | ||
Price Target Range | ||
High | 45.00 (HC Wainwright & Co., 275.94%) | Buy |
Median | 38.00 (217.46%) | |
Low | 31.00 (Wedbush, 158.98%) | Buy |
Average | 38.00 (217.46%) | |
Total | 2 Buy | |
Avg. Price @ Call | 11.89 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Wedbush | 12 Feb 2025 | 31.00 (158.98%) | Buy | 12.13 |
06 Feb 2025 | 31.00 (158.98%) | Buy | 12.60 | |
HC Wainwright & Co. | 27 Jan 2025 | 45.00 (275.94%) | Buy | 11.65 |
06 Dec 2024 | 42.00 (250.88%) | Buy | 21.10 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |